As an advisory board member of Bloomberg BNA’s Medical Devices Law & Industry Report, Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted throughout the publication’s outlook for the coming year titled “OUTLOOOK 2016: Lab Tests, Cybersecurity, Off-Label Use Among Top Device Issues.”
Following is an excerpt:
‘‘Pharmaceutical companies seem poised to dive in at an accelerated rate into digital health,’’ Thompson observed. ‘‘This means that pharmaceutical companies will continue to partner with Silicon Valley tech companies to develop software and wearables that will supplement drug therapy.’’
‘‘These technologies can help optimize the timing and dosage of pharmaceutical products, as well as enhance compliance with drug regimens,’’ he said.
Nonetheless, Thompson said, many issues are swirling around whether these products are medical devices, and, if so, how they should be regulated.
